Exemplis Discimus 2005, 149(2):225-236

Donec eros augue, posuere et, aliquam sed, tristique et, leo.

Oret Hwanga,b, Voka Faroamera, Cutter Chiasa, Thew Bongab
a Institute of Oral Medicine and Oral Diagnosis, Teaching Hospital of Thisspias, Coruscant Republic
b 1st Clinic of Medical Informatics, Quence University Hospital, Republic of Kamino

Vivamus placerat elit ac sem facilisis lobortis. Cras sit amet velit convallis tortor aliquam tempus. In mi libero, volutpat vel, dignissim semper, elementum a, lorem. Integer eros purus, sagittis nec, malesuada tincidunt, imperdiet nec, erat. Praesent leo sapien, pellentesque vel, adipiscing vel, scelerisque interdum, nisl. Praesent erat quam, pulvinar id, vulputate eu, pretium et, sapien. Praesent nisl sem, rhoncus vel, facilisis in, tincidunt ac, enim. Duis orci felis, blandit non, tempor vel, ornare sed, velit.

Kľúčové slová: Duis ac tellus, In pharetra, Etiam nunc, Nullam lacinia, Phasellus venenatis

Vložený: June 10, 2005; Přijatý: September 25, 2005; Uverejnené: December 1, 2005 


Referencie

  1. Borkakoti N. (2000) Structural studies of matrix metalloproteinases. J Mol Med. 78, 261-268. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  2. Shapiro SD. (1998) Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol. 10, 602-608. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  3. Zagris N. (2001) Extracellular matrix in development of the early embryo. Micron. 32, 427-438. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  4. Birkedal-Hansen H. (1995) Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol. 7, 728-735. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  5. Arthur MJ. (2000) Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 279, G245-249. Prejsť na PubMed...
  6. Brinckerhoff CE, Rutter JL, Benbow U. (2000) Interstitial collagenases as markers of tumor progression. Clin Cancer Res. 6, 4823-4830. Prejsť na PubMed...
  7. Obermuller N, Morente N, Kranzlin B, Gretz N, Witzgall R. (2001) A possible role for metalloproteinases in renal cyst development. Am J Physiol Renal Physiol. 280, F540-550. Prejsť na PubMed...
  8. Stetler-Stevenson WG, Yu AE. (2001) Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol. 11, 143-152. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  9. Lee MH, Murphy G. (2004) Matrix metalloproteinases at a glance. J Cell Sci. 117, 4015-4016. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  10. Ala-aho R, Kahari VM. (2005) Collagenases in cancer. Biochimie. 87, 273-286. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  11. Overall CM, Lopez-Otin C. (2002) Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2, 657-672. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  12. Becker JW, Marcy AI, Rokosz LL, Axel MG, Burbaum JJ, Fitzgerald PM, Cameron PM, Esser CK, Hagmann WK, et al. (1995) Stromelysin-1: three-dimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme. Protein Sci. 4, 1966-1976. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  13. Van Wart HE, Birkedal-Hansen H. (1990) The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A. 87, 5578-5582. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  14. Stocker W, Gomis-Ruth FX, Bode W, Zwilling R. (1993) Implications of the three-dimensional structure of astacin for the structure and function of the astacin family of zinc-endopeptidases. Eur J Biochem. 214, 215-231. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  15. Dhanaraj V, Ye QZ, Johnson LL, Hupe DJ, Ortwine DF, Dunbar JB, Jr., Rubin JR, Pavlovsky A, Humblet C, et al. (1996) X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily. Structure. 4, 375-386. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  16. Gomis-Ruth FX, Gohlke U, Betz M, Knauper V, Murphy G, Lopez-Otin C, Bode W. (1996) The helping hand of collagenase-3 (MMP-13): 2.7 A crystal structure of its C-terminal haemopexinlike domain. J Mol Biol. 264, 556-566. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  17. Bode W. (1995) A helping hand for collagenases: the haemopexinlike domain. Structure. 3, 527-530. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  18. Buttner FH, Hughes CE, Margerie D, Lichte A, Tschesche H, Caterson B, Bartnik E. (1998) Membrane type 1 matrix metalloproteinase (MT1-MMP) cleaves the recombinant aggrecan substrate rAgg1mut at the aggrecanase and the MMP sites. Characterization of MT1-MMP catabolic activities on the interglobular domain of aggrecan. Biochem J. 333, 159-165. Prejsť na PubMed...
  19. Nagase H, Woessner JF, Jr. (1999) Matrix metalloproteinases. J Biol Chem. 274, 21491-21494. Prejsť k pôvodnému zdroju...
  20. Ye S. (2000) Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol. 19, 623-629. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  21. Murphy G, Nguyen Q, Cockett MI, Atkinson SJ, Allan JA, Knight CG, Willenbrock F, Docherty AJ. (1994) Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. J Biol Chem. 269, 6632-6636. Prejsť na PubMed...
  22. Uria JA, Lopez-Otin C. (2000) Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. Cancer Res. 60, 4745-4751. Prejsť na PubMed...
  23. Wilson CL, Matrisian LM. (1996) Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol. 28, 123-136. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  24. Llano E, Pendas AM, Knauper V, Sorsa T, Salo T, Salido E, Murphy G, Simmer JP, Bartlett JD, et al. (1997) Identification and structural and functional characterization of human enamelysin (MMP- 20). Biochemistry. 36, 15101-15108. Prejsť k pôvodnému zdroju...
  25. Lohi J, Wilson CL, Roby JD, Parks WC. (2001) Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury. J Biol Chem. 276, 10134-10144. Prejsť k pôvodnému zdroju...
  26. Pendas AM, Knauper V, Puente XS, Llano E, Mattei MG, Apte S, Murphy G, Lopez-Otin C. (1997) Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution. J Biol Chem. 272, 4281-4286. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  27. Stracke JO, Hutton M, Stewart M, Pendas AM, Smith B, Lopez- Otin C, Murphy G, Knauper V. (2000) Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19. Evidence for a role as a potent basement membrane degrading enzyme. J Biol Chem. 275, 14809-14816. Prejsť k pôvodnému zdroju...
  28. Marchenko GN, Ratnikov BI, Rozanov DV, Godzik A, Deryugina EI, Strongin AY. (2001) Characterization of matrix metalloproteinase- 26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. Biochem J. 356, 705-718. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  29. Pei D, Majmudar G, Weiss SJ. (1994) Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. J Biol Chem. 269, 25849-25855.
  30. Ohnishi J, Ohnishi E, Jin M, Hirano W, Nakane D, Matsui H, Kimura A, Sawa H, Nakayama K, et al. (2001) Cloning and characterization of a rat ortholog of MMP-23 (matrix metalloproteinase- 23), a unique type of membrane-anchored matrix metalloproteinase and conditioned switching of its expression during the ovarian follicular development. Mol Endocrinol. 15, 747-764. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  31. Imai K, Hiramatsu A, Fukushima D, Pierschbacher MD, Okada Y. (1997) Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. Biochem J. 322, 809-814. Prejsť na PubMed...
  32. Prockop DJ, Kivirikko KI. (1995) Collagens: molecular biology, diseases, and potentials for therapy. Annu Rev Biochem. 64, 403- 434. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  33. Netzel-Arnett S, Fields GB, Birkedal-Hansen H, Van Wart HE, Fields G. (1991) Sequence specificities of human fibroblast and neutrophil collagenases. J Biol Chem. 266, 6747-6755. Prejsť na PubMed...
  34. Aimes RT, Quigley JP. (1995) Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem. 270, 5872-5876. Prejsť na PubMed...
  35. Allan JA, Hembry RM, Angal S, Reynolds JJ, Murphy G. (1991) Binding of latent and high Mr active forms of stromelysin to collagen is mediated by the C-terminal domain. J Cell Sci. 99, 789- 795. Prejsť na PubMed...
  36. Murphy G, Allan JA, Willenbrock F, Cockett MI, OConnell JP, Docherty AJ. (1992) The role of the C-terminal domain in collagenase and stromelysin specificity. J Biol Chem. 267, 9612-9618. Prejsť na PubMed...
  37. Knauper V, Lopez-Otin C, Smith B, Knight G, Murphy G. (1996) Biochemical characterization of human collagenase-3. J Biol Chem. 271, 1544-1550. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  38. De Souza SJ, Pereira HM, Jacchieri S, Brentani RR. (1996) Collagen/collagenase interaction: does the enzyme mimic the conformation of its own substrate? Faseb J. 10, 927-930. Prejsť na PubMed...
  39. Chung L, Shimokawa K, Dinakarpandian D, Grams F, Fields GB, Nagase H. (2000) Identification of the (183)RWTNNFREY(191) region as a critical segment of matrix metalloproteinase 1 for the expression of collagenolytic activity. J Biol Chem. 275, 29610- 29617. Prejsť k pôvodnému zdroju...
  40. Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y. (1997) Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem. 272, 2446-2451. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  41. Wang Y, Johnson AR, Ye QZ, Dyer RD. (1999) Catalytic activities and substrate specificity of the human membrane type 4 matrix metalloproteinase catalytic domain. J Biol Chem. 274, 33043- 33049. Prejsť k pôvodnému zdroju...
  42. Ellerbroek SM, Wu YI, Stack MS. (2001) Type I collagen stabilization of matrix metalloproteinase-2. Arch Biochem Biophys. 390, 51-56. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  43. Senior RM, Griffin GL, Fliszar CJ, Shapiro SD, Goldberg GI, Welgus HG. (1991) Human 92- and 72-kilodalton type IV collagenases are elastases. J Biol Chem. 266, 7870-7875. Prejsť na PubMed...
  44. Liu Z, Zhou X, Shapiro SD, Shipley JM, Twining SS, Diaz LA, Senior RM, Werb Z. (2000) The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell. 102, 647-655. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  45. Kridel SJ, Chen E, Kotra LP, Howard EW, Mobashery S, Smith JW. (2001) Substrate hydrolysis by matrix metalloproteinase-9. J Biol Chem. 276, 20572-20578. Prejsť k pôvodnému zdroju...
  46. Gronski TJ, Jr., Martin RL, Kobayashi DK, Walsh BC, Holman MC, Huber M, Van Wart HE, Shapiro SD. (1997) Hydrolysis of a broad spectrum of extracellular matrix proteins by human macrophage elastase. J Biol Chem. 272, 12189-12194. Prejsť k pôvodnému zdroju...
  47. Stracke JO, Fosang AJ, Last K, Mercuri FA, Pendas AM, Llano E, Perris R, Di Cesare PE, Murphy G, et al. (2000) Matrix metalloproteinases 19 and 20 cleave aggrecan and cartilage oligomeric matrix protein (COMP). FEBS Lett. 478, 52-56. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  48. Auble DT, Brinckerhoff CE. (1991) The AP-1 sequence is necessary but not sufficient for phorbol induction of collagenase in fibroblasts. Biochemistry. 30, 4629-4635. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  49. Duivenvoorden WC, Hirte HW, Singh G. (1999) Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. Clin Exp Metastasis. 17, 27-34. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  50. Wada K, Sato H, Kinoh H, Kajita M, Yamamoto H, Seiki M. (1998) Cloning of three Caenorhabditis elegans genes potentially encoding novel matrix metalloproteinases. Gene. 211, 57-62. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  51. Nagase H, Suzuki K, Morodomi T, Enghild JJ, Salvesen G. (1992) Activation mechanisms of the precursors of matrix metalloproteinases 1, 2 and 3. Matrix Suppl. 1, 237-244. Prejsť na PubMed...
  52. Nagase H. (1998) Cell surface activation of progelatinase A (proMMP- 2) and cell migration. Cell Res. 8, 179-186. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  53. Spiegel S, Foster D, Kolesnick R. (1996) Signal transduction through lipid second messengers. Curr Opin Cell Biol. 8, 159- 167. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  54. Korzus E, Nagase H, Rydell R, Travis J. (1997) The mitogen-activated protein kinase and JAK-STAT signaling pathways are required for an oncostatin M-responsive element-mediated activation of matrix metalloproteinase 1 gene expression. J Biol Chem. 272, 1188-1196. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  55. Fisher GJ, Datta SC, Talwar HS, Wang ZQ, Varani J, Kang S, Voorhees JJ. (1996) Molecular basis of sun-induced premature skin ageing and retinoid antagonism. Nature. 379, 335-339. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  56. Brenneisen P, Wenk J, Klotz LO, Wlaschek M, Briviba K, Krieg T, Sies H, Scharffetter-Kochanek K. (1998) Central role of Ferrous/ Ferric iron in the ultraviolet B irradiation-mediated signaling pathway leading to increased interstitial collagenase (matrix-degrading metalloprotease (MMP)-1) and stromelysin-1 (MMP-3) mRNA levels in cultured human dermal fibroblasts. J Biol Chem. 273, 5279-5287. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  57. Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, Nabeshima K. (1995) The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res. 55, 434-439. Prejsť na PubMed...
  58. Lim M, Martinez T, Jablons D, Cameron R, Guo H, Toole B, Li JD, Basbaum C. (1998) Tumor-derived EMMPRIN (extracellular matrix metalloproteinase inducer) stimulates collagenase transcription through MAPK p38. FEBS Lett. 441, 88-92. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  59. Li YY, McTiernan CF, Feldman AM. (2000) Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res. 46, 214-224. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  60. Xie B, Laouar A, Huberman E. (1998) Fibronectin-mediated cell adhesion is required for induction of 92-kDa type IV collagenase/ gelatinase (MMP-9) gene expression during macrophage differentiation. The signaling role of protein kinase C-beta. J Biol Chem. 273, 11576-11582. Prejsť k pôvodnému zdroju...
  61. Seltzer JL, Lee AY, Akers KT, Sudbeck B, Southon EA, Wayner EA, Eisen AZ. (1994) Activation of 72-kDa type IV collagenase/ gelatinase by normal fibroblasts in collagen lattices is mediated by integrin receptors but is not related to lattice contraction. Exp Cell Res. 213, 365-374. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  62. Lijnen HR, Lupu F, Moons L, Carmeliet P, Goulding D, Collen D. (1999) Temporal and topographic matrix metalloproteinase expression after vascular injury in mice. Thromb Haemost. 81, 799-807. Prejsť na PubMed...
  63. Springman EB, Angleton EL, Birkedal-Hansen H, Van Wart HE. (1992) Biochemical basis for multiple modes of activation of human fibroblast collagenase. Matrix Suppl. 1, 76-77. Prejsť na PubMed...
  64. Nagase H. (1997) Activation mechanisms of matrix metalloproteinases. Biol Chem. 378, 151-160. Prejsť na PubMed...
  65. Suzuki K, Enghild JJ, Morodomi T, Salvesen G, Nagase H. (1990) Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin). Biochemistry. 29, 10261-10270. Prejsť k pôvodnému zdroju...
  66. Suzuki K, Lees M, Newlands GF, Nagase H, Woolley DE. (1995) Activation of precursors for matrix metalloproteinases 1 (interstitial collagenase) and 3 (stromelysin) by rat mast-cell proteinases I and II. Biochem J. 305, 301-306. Prejsť na PubMed...
  67. Suzuki D, Miyazaki M, Jinde K, Koji T, Yagame M, Endoh M, Nomoto Y, Sakai H. (1997) In situ hybridization studies of matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1 and type IV collagen in diabetic nephropathy. Kidney Int. 52, 111-119. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  68. Okada Y, Morodomi T, Enghild JJ, Suzuki K, Yasui A, Nakanishi I, Salvesen G, Nagase H. (1990) Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur J Biochem. 194, 721-730. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  69. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. (1994) A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature. 370, 61-65. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  70. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. (1995) Mechanism of cell surface activation of 72- kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem. 270, 5331-5338. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  71. Murphy G. (1995) Matrix metalloproteinases and their inhibitors. Acta Orthop Scand Suppl. 266, 55-60. Prejsť na PubMed...
  72. Springman EB, Angleton EL, Birkedal-Hansen H, Van Wart HE. (1990) Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a cysteine switch mechanism for activation. Proc Natl Acad Sci U S A. 87, 364-368. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  73. Kolkenbrock H, Orgel D, Hecker-Kia A, Noack W, Ulbrich N. (1991) The complex between a tissue inhibitor of metalloproteinases (TIMP-2) and 72-kDa progelatinase is a metalloproteinase inhibitor. Eur J Biochem. 198, 775-781. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  74. Kolkenbrock H, Hecker-Kia A, Orgel D, Ruppitsch W, Ulbrich N. (1994) Activity of ternary gelatinase A-TIMP-2-matrix metalloproteinase complexes. Biol Chem Hoppe Seyler. 375, 589-595. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  75. Ogata Y, Itoh Y, Nagase H. (1995) Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases. J Biol Chem. 270, 18506-18511. Prejsť k pôvodnému zdroju...
  76. Ries C, Petrides PE. (1995) Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol Chem Hoppe Seyler. 376, 345-355. Prejsť na PubMed...
  77. Fabunmi RP, Baker AH, Murray EJ, Booth RF, Newby AC. (1996) Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases- 1, -2, and -3 in rabbit aortic smooth muscle cells. Biochem J. 315, 335-342. Prejsť na PubMed...
  78. Apte SS, Hayashi K, Seldin MF, Mattei MG, Hayashi M, Olsen BR. (1994) Gene encoding a novel murine tissue inhibitor of metalloproteinases (TIMP), TIMP-3, is expressed in developing mouse epithelia, cartilage, and muscle, and is located on mouse chromosome 10. Dev Dyn. 200, 177-197. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  79. Anand-Apte B, Bao L, Smith R, Iwata K, Olsen BR, Zetter B, Apte SS. (1996) A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. Biochem Cell Biol. 74, 853-862. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  80. Tummalapalli CM, Heath BJ, Tyagi SC. (2001) Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts. J Cell Biochem. 80, 512-521. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  81. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. (1992) Growth-promoting activity of tissue inhibitor of metalloproteinases- 1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett. 298, 29-32. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  82. Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A. (1994) Cell growth-promoting activity of tissue inhibitor of metalloproteinases- 2 (TIMP-2). J Cell Sci. 107, 2373-2379. Prejsť na PubMed...
  83. Ponton A, Coulombe B, Skup D. (1991) Decreased expression of tissue inhibitor of metalloproteinases in metastatic tumor cells leading to increased levels of collagenase activity. Cancer Res. 51, 2138-2143. Prejsť na PubMed...
  84. Tyagi SC. (1997) Proteinases and myocardial extracellular matrix turnover. Mol Cell Biochem. 168, 1-12. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  85. Maisch B. (1996) Ventricular remodeling. Cardiology. 87, 2-10. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  86. Pelouch V, Jirmar R. (1993) Biochemical characteristics of cardiac collagen and its role in ventricular remodelling following infarction. Physiol Res. 42, 283-292. Prejsť na PubMed...
  87. Schacherer C, Koops D, Wiemer J, Hartmann A, Weis M, Klepzig H, Zeiher AM, Olbrich HG. (1999) Extracellular matrix structure after heart transplantation. Int J Cardiol. 68, 115-120. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  88. Weber KT, Sun Y, Tyagi SC, Cleutjens JP. (1994) Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol. 26, 279-292. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  89. Jones FS, Jones PL. (2000) The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn. 218, 235-259. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  90. Ross RS, Borg TK. (2001) Integrins and the myocardium. Circ Res. 88, 1112-1119. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  91. Cleutjens JP. (1996) The role of matrix metalloproteinases in heart disease. Cardiovasc Res. 32, 816-821. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  92. Tyagi SC, Kumar S, Voelker DJ, Reddy HK, Janicki JS, Curtis JJ. (1996) Differential gene expression of extracellular matrix components in dilated cardiomyopathy. J Cell Biochem. 63, 185-198. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  93. Tyagi SC, Campbell SE, Reddy HK, Tjahja E, Voelker DJ. (1996) Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts. Mol Cell Biochem. 155, 13-21. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  94. Tyagi SC, Matsubara L, Weber KT. (1993) Direct extraction and estimation of collagenase(s) activity by zymography in microquantities of rat myocardium and uterus. Clin Biochem. 26, 191-198. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  95. Tyagi SC, Ratajska A, Weber KT. (1993) Myocardial matrix metalloproteinase(s): localization and activation. Mol Cell Biochem. 126, 49-59. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  96. Cleutjens JP, Kandala JC, Guarda E, Guntaka RV, Weber KT. (1995) Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol. 27, 1281-1292. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  97. Carlyle WC, Jacobson AW, Judd DL, Tian B, Chu C, Hauer KM, Hartman MM, McDonald KM. (1997) Delayed reperfusion alters matrix metalloproteinase activity and fibronectin mRNA expression in the infarct zone of the ligated rat heart. J Mol Cell Cardiol. 29, 2451-2463. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  98. Lindsey M, Wedin K, Brown MD, Keller C, Evans AJ, Smolen J, Burns AR, Rossen RD, Michael L, et al. (2001) Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation. 103, 2181-2187. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  99. Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW, Schulz R. (2000) Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation. 101, 1833- 1839. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  100. Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, Lopez-Anaya A, McClure KF, Mitchell PG, Libby P, et al. (1999) Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation. 99, 3063-3070. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  101. Robert V, Besse S, Sabri A, Silvestre JS, Assayag P, Nguyen VT, Swynghedauw B, Delcayre C. (1997) Differential regulation of matrix metalloproteinases associated with aging and hypertension in the rat heart. Lab Invest. 76, 729-738. Prejsť na PubMed...
  102. Li YY, Feldman AM, Sun Y, McTiernan CF. (1998) Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation. 98, 1728-1734. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  103. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ, 3rd, Spinale FG. (1998) Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation. 97, 1708-1715. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  104. Tyagi SC. (1998) Extracellular matrix dynamics in heart failure: a prospect for gene therapy. J Cell Biochem. 68, 403-410. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  105. Kukacka J, Bíbová J, Ruskoaho H, Pelouch V. (2002) Chronic hypoxia alters expression of extracellular matrix components in rat. Phys Res. 51, P21.
  106. Kukacka J, Bíbová J, Ruskoaho H, Pelouch V. (2002) The effect of hypoxia and hypercapnia on remodeling of extracellular matrix in rat heart. Faseb J. 16, A1116.
  107. Tyagi SC, Kumar SG, Haas SJ, Reddy HK, Voelker DJ, Hayden MR, Demmy TL, Schmaltz RA, Curtis JJ. (1996) Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardio myopathy. J Mol Cell Cardiol. 28, 1415-1428. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  108. Spinale FG, Coker ML, Thomas CV, Walker JD, Mukherjee R, Hebbar L. (1998) Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res. 82, 482-495. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  109. Coker ML, Thomas CV, Clair MJ, Hendrick JW, Krombach RS, Galis ZS, Spinale FG. (1998) Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. Am J Physiol. 274, H1516-1523. Prejsť na PubMed...
  110. Gunja-Smith Z, Morales AR, Romanelli R, Woessner JF, Jr. (1996) Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links. Am J Pathol. 148, 1639-1648. Prejsť na PubMed...
  111. Brower GL, Janicki JS. (2001) Contribution of ventricular remodeling to pathogenesis of heart failure in rats. Am J Physiol Heart Circ Physiol. 280, H674-683. Prejsť na PubMed...
  112. Botos I, Scapozza L, Zhang D, Liotta LA, Meyer EF. (1996) Batimastat, a potent matrix mealloproteinase inhibitor, exhibits an unexpected mode of binding. Proc Natl Acad Sci U S A. 93, 2749-2754. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  113. Whittaker M, Floyd CD, Brown P, Gearing AJ. (2001) Design and therapeutic application of matrix metalloproteinase inhibitors. (Chem. Rev. 1999, 99, 2735-2776. Published on the web september 8, 1999). Chem Rev. 101, 2205-2206. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  114. Xue CB, He X, Roderick J, DeGrado WF, Cherney RJ, Hardman KD, Nelson DJ, Copeland RA, Jaffee BD, et al. (1998) Design and synthesis of cyclic inhibitors of matrix metalloproteinases and TNF-alpha production. J Med Chem. 41, 1745-1748. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  115. Li YY, Kadokami T, Wang P, McTiernan CF, Feldman AM. (2002) MMP inhibition modulates TNF-[alpha] transgenic mouse phenotype early in the development of heart failure. Am J Physiol Heart Circ Physiol. 282, H983-H989. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  116. Heath EI, Grochow LB. (2000) Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs. 59, 1043-1055. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  117. Heath EI, OReilly S, Humphrey R, Sundaresan P, Donehower RC, Sartorius S, Kennedy MJ, Armstrong DK, Carducci MA, et al. (2001) Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors. Cancer Chemother Pharmacol. 48, 269-274. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  118. Spinale FG, Coker ML, Krombach SR, Mukherjee R, Hallak H, Houck WV, Clair MJ, Kribbs SB, Johnson LL, et al. (1999) Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res. 85, 364-376. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  119. Wang W, Sawicki G, Schulz R. (2002) Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc Res. 53, 165-174. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  120. Peterson JT, Hallak H, Johnson L, Li H, OBrien PM, Sliskovic DR, Bocan TM, Coker ML, Etoh T, et al. (2001) Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation. 103, 2303-2309. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  121. Li H, Simon H, Bocan TM, Peterson JT. (2000) MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition. Cardiovasc Res. 46, 298-306. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  122. Hidalgo M, Eckhardt SG. (2001) Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 93, 178-193. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  123. Golub LM, Ramamurthy N, McNamara TF, Gomes B, Wolff M, Casino A, Kapoor A, Zambon J, Ciancio S, et al. (1984) Tetracyclines inhibit tissue collagenase activity. A new mechanism in the treatment of periodontal disease. J Periodontal Res. 19, 651-655. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  124. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. (1998) Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res. 12, 12-26. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  125. Rodan GA, Fleisch HA. (1996) Bisphosphonates: mechanisms of action. J Clin Invest. 97, 2692-2696. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  126. Ichinose Y, Migita K, Nakashima T, Kawakami A, Aoyagi T, Eguchi K. (2000) Effects of bisphosphonate on the release of MMP-2 from cultured human osteoblasts. Tohoku J Exp Med. 192, 111-118. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  127. Teronen O, Heikkila P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R, Teronen A, Maisi P, Sorsa T. (1999) MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci. 878, 453-465. Prejsť k pôvodnému zdroju... Prejsť na PubMed...